Tributyrin
Also known as: glyceryl tributyrate, butyrate prodrug, tributyrylglycerol, short-chain fatty acid triglyceride
Effective Dosage
No established dose from provided studies
What the Science Says
Tributyrin is a naturally occurring fat found in butter that acts as a prodrug for butyrate — a short-chain fatty acid your gut bacteria normally produce. Because butyrate is rapidly broken down before reaching the bloodstream, tributyrin is being studied as a more bioavailable way to deliver butyrate to the body. Early-stage human trials are exploring its potential roles in Parkinson's disease, depression, immune regulation, and cancer, but no large clinical trials have confirmed meaningful benefits in any of these areas.
What It Doesn't Do
Not proven to treat or prevent any disease. Won't stimulate gut hormone release like GLP-1 — one human study found tributyrin had no effect on GLP-1, GIP, or other satiety hormones. No evidence it aids weight loss. The cancer research showed no tumor shrinkage in patients. The immunonutrition studies (combined with other ingredients) showed no improvement in surgical recovery or inflammation markers. Don't confuse early-stage research with proven benefits.
Evidence-Based Benefits
Tributyrin is a prodrug of butyrate that resists gastric acid and is hydrolyzed to butyrate by pancreatic lipases in the small intestine, with approximately 40-49% converted to butyrate in the small intestine and the remainder reaching the colon (PMID: 41473189). In preclinical transplant models, oral tributyrin extended allograft survival via regulatory T cell-mediated immune modulation (PMID: 41554342). A small open-label study in Parkinson's disease patients found it was safe and well-tolerated over 30 days, with preliminary evidence of target engagement on gut-brain axis biomarkers (PMID: 41271518).
Weak EvidenceEffective at: 500-4000 mg daily (human studies range widely; no consensus established)
Source: auto-research
Absorption & Bioavailability
Moderate — tributyrin is better absorbed than sodium butyrate because it bypasses rapid colonocyte metabolism, achieving measurable plasma butyrate levels. However, a cancer pharmacology study found considerable variability between individuals, with median butyrate concentrations of only ~52 µM even at high doses.
Red Flags to Watch For
- All human clinical evidence is very early-stage (small pilot studies, open-label, or protocol papers only — no completed large RCTs)
- Doses used in studies vary widely and have not been standardized for consumer supplementation
- One immunonutrition study found a trend toward higher CRP (inflammation marker) in the tributyrin-containing formula group compared to controls
- Most promising findings (transplant tolerance, Parkinson's, depression) come from animal models or very small open-label human studies with no control group
- 16 registered supplement products exist despite no strong clinical evidence — marketing may far outpace the science
Products Containing Tributyrin
See how Tributyrin is used in these analyzed products:
Research Sources
- PubMed
- NIH DSLD
This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-04-06